Reviewed profile

food and beverage brand · public preview

Saxenda

Retail brand

Public category
Retail brand
Brand tier
mainstream brand
Headquarters
Denmark
Is this your company?Claim Saxenda to get found by buyers, add products and certifications, correct your details, and be eligible when Talio’s AI recommends suppliers.Let our AI make the introductionGet a warm, researched intro to Saxenda — no cold outreach.
Report a changeLog in for full recordLast reviewed 19 May 2026 · public preview data

Overview

What Saxenda covers.

Saxenda is a prescription injectable medication containing liraglutide, indicated for weight management in adults with obesity or overweight and adolescents aged 12 to 17. Developed by Novo Nordisk, the treatment is intended to be used in conjunction with a reduced-calorie diet and increased physical activity. It functions as a GLP-1 receptor agonist to assist patients in achieving and maintaining weight loss.

  • Positioned as a mainstream brand.
  • Headquartered in Denmark.

FAQ

Questions this page answers.

What does Saxenda do?

Saxenda is a food and beverage brand based in Denmark, tracked in Talio's food and beverage intelligence platform.

Is this the full Talio record?

No. This page is a public preview; proprietary metrics and workflow features remain inside authenticated Talio.

Own this company?

Get found by buyers — and the AI that recommends suppliers.

Claim this profile to appear in buyer searches, add your products and certifications, correct outdated details, and stay eligible when Talio's AI recommends suppliers.

Claiming grants reviewed submission rights only — not direct editing, suppression, or ownership of Talio-derived intelligence. Verification required.

Claim this pageLog in for full recordReport a change

Public preview data only · proprietary metrics remain in authenticated Talio.